RYTM
RHYTHM PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$91.89
+6.31%Year over year
Reported trailing growth
- Revenue
- +61.0%
- EBITDA
- -2.5%
- EBIT
- -0.6%
- EPS
- +6.5%
- Free cash flow
- +23.7%
- Operating cash flow
- +25.1%
Forward estimates
Based on analyst estimates
- Revenue
- +73.0%
- EBITDA
- +49.0%
- EPS
- +37.7%
Three-year CAGR
- Revenue
- +100.2%
- EBITDA
- +26.9%
- EBIT
- +27.7%
- Net income
- +24.6%
- EPS
- +28.3%
- Free cash flow
- -2.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026